---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-017856"
form_type: "8-K"
ticker: "STIM"
cik: "0001227636"
company_name: "Neuronetics, Inc."
filed_at: "2023-11-07T23:59:59+00:00"
generated_at: "2026-06-08T13:39:52.261299+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Neuronetics Q3 revenue $17.9M (+8% YoY); net loss $(9.4)M; narrows FY 2023 guidance

## Summary
- Revenue $17.9M (+8% YoY); record US treatment session revenue $13.1M (+10% YoY).
- Gross margin 65.8% (down from 78.4%) due to $1.9M inventory write-off; adjusted 77.3%.
- Net loss $(9.4)M or $(0.33)/share vs $(7.6)M or $(0.28)/share last year.
- Drew down remaining $22.5M from SLR credit facility; cash $35.8M vs $70.3M at Dec 31, 2022.
- FY 2023 revenue guidance narrowed to $70-72M; Q4 revenue expected $19-21M.

## SEC filing metadata
- accession: 0001558370-23-017856
- form_type: 8-K
- ticker: STIM
- cik: 0001227636
- company_name: Neuronetics, Inc.
- filed_at: 2023-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1227636/000155837023017856/0001558370-23-017856-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1227636/000155837023017856/stim-20231107x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-017856
- JSON: https://secwatch.observer/filing/0001558370-23-017856.json
- Plain text: https://secwatch.observer/filing/0001558370-23-017856.txt

## Key facts
- Earnings Releases
  Neuronetics, Inc. reported the three months ended September 30, 2023 results: revenue $17.9 million, net income $(9.4) million, EPS $(0.33) per share.
  - Period: the three months ended September 30, 2023
  - Revenue: $17.9 million
  - Net income: $(9.4) million
  - EPS: $(0.33) per share
  - Result: reported results
  source text: therapies in the world, today announced its financial and operating results for the third quarter of 2023. Third Quarter 2023 Highlights ● Third quarter 2023 revenue of $17.9 million, an increase of 8% over the third quarter of 2022 ● Record U.S. treatment session revenue of $13.1 million ● Shipped 43 NeuroStar systems ​ Recent Operational Highlights ●
  evidence_url: https://www.sec.gov/Archives/edgar/data/1227636/000155837023017856/0001558370-23-017856-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.